Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

Deucravacitinib has been observed as a safe and efficacious treatment for adults with moderate to severe plaque psoriasis for up to 4 years.

Akeso, Inc. (9926.HK) ('Akeso' or the 'Company') is pleased to announce that ebdarokimab, an investigational monoclonal antibody developed by the company, has received marketing approval from the ...

A growing momentum for earlier treatment of psoriasis has the potential to improve outcomes with oral therapies and biologics ...

Two phase 2 trials with different selective TYK2 inhibitors produce high rates of efficacy in moderate to severe plaque ...

On lighter skin, plaque ... medications such as biologics, which are derived from natural sources and target the immune system. Although psoriasis causes and treatment do not differ by skin ...

Lichenification occurs when repeated scratching or rubbing causes skin to thicken and become leathery. Certain skincare and treatment options may help reduce the reaction.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

There are, of course, risks to any investment, and Johnson & Johnson has them, too. The talc lawsuits are a wildcard and its ...

March 24, 2025 – The FDA has approved a new Crohn’s disease treatment called guselkumab, which, unlike similar drugs ... the nod for treating plaque psoriasis. The antibody was also ...

J&J is hoping to show that the peptide drug can be a more patient-friendly alternative to injectable biologics for plaque psoriasis, including drugs working on IL-23, such as J&J's own Tremfya ...

Let's dig into what Lilly's business looks like beyond weight loss treatments ... several other market-leading medications that are used to treat cancer, plaque psoriasis, eczema, and other ...